Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02823327 · ClinicalTrials.gov registry record
Clinical and Genomic Factors for Prognosis of AIDS Primary Effusion Lymphoma
A clinical trial, sponsored by AIDS Malignancy Consortium.
- Terminated
- Registry status
- 25
- Enrollment target
NCT02823327 is a clinical trial that was terminated before completion, run by AIDS Malignancy Consortium. The registered enrollment target is 25 participants.
The verdict
NCT02823327 was terminated before completion, sponsored by AIDS Malignancy Consortium.
- TERMINATED
- Registry status
- 25 participants
- Enrollment target
Study Summary
This research trial studies clinical factors and gene expression analysis for prognosis in tissue samples from patients with acquired immune deficiency syndrome (AIDS)-related primary effusion lymphoma. Gathering health information over time and studying samples of tissue from patients in the laboratory may help doctors learn about the prognosis of patients with AIDS-related primary effusion lymphoma.
Interventions
- OTHER Medical Chart Review
- GENETIC Laboratory Biomarker Analysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2016-10-11 |
| Est. Completion | 2023-02-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02823327
The ClinicalTrials.gov registry entry for NCT02823327 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AIDS Malignancy Consortium, which has 45 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Medical Chart Review is the first listed.
NCT02823327 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02823327 about?
NCT02823327 is a clinical study titled "Clinical and Genomic Factors for Prognosis of AIDS Primary Effusion Lymphoma". This research trial studies clinical factors and gene expression analysis for prognosis in tissue samples from patients with acquired immune deficiency syndrome (AIDS)-related primary effusion lymphoma. Gathering health information over time and studying samples of tissue from patients in the labora...
What is the current status of trial NCT02823327?
This trial is currently terminated. The enrollment target is 25 participants. The study started on 2016-10-11. Estimated completion is 2023-02-03.
What interventions are being tested in trial NCT02823327?
The interventions under investigation include: Medical Chart Review (OTHER), Laboratory Biomarker Analysis (GENETIC).
Who is sponsoring clinical trial NCT02823327?
This trial is sponsored by AIDS Malignancy Consortium, which has 45 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.